Unleashing the Titans: The Gen-011 Neoantigen-Targeted Peripheral T Cell Therapy for Solid Tumors

Time: 6:00 pm
day: Day One


• Adoptive T cell therapies have resulted in unprecedented efficacy against solid tumors
• Prioritizing neoantigens with the ATLASTM bioassay identifies the right targets and avoids pro-tumor InhibigensTM
• The GEN-011 neoantigen-targeted peripheral T cells (NPTs) have broad specificity and are non-exhausted, polyfunctional, cytolytic cells
• The TITAN-1 clinical trial is ongoing (NCT04596033)